CR8152A - Modulador de receptor canabinoide - Google Patents

Modulador de receptor canabinoide

Info

Publication number
CR8152A
CR8152A CR8152A CR8152A CR8152A CR 8152 A CR8152 A CR 8152A CR 8152 A CR8152 A CR 8152A CR 8152 A CR8152 A CR 8152A CR 8152 A CR8152 A CR 8152A
Authority
CR
Costa Rica
Prior art keywords
canabinoid
optionally
ring
receiver modulator
substituted
Prior art date
Application number
CR8152A
Other languages
English (en)
Inventor
Ohkawa Shigenori
Tsukamoto Tetsuya
Kiyota Yoshihiro
Goto Mika
Yamamoto Shouzou
Shimojou Masato
Setou Masaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR8152A publication Critical patent/CR8152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Un receptor modulador canabinoide el cual contiene un compuesto representado por la formula (I0): (I0) (donde X representa oxigeno, etc.; R0 representa opcionalmente la acilamina sustituida; el anillo A° representa un anillo de benceno que posee opcionalmente un substituto ademas de R°; y el anillo B representa opcionalmente heterociclos de cinco miembros sustituidos), una sal de un compuesto, o una prodroga de alguno de estos.
CR8152A 2003-06-26 2005-12-15 Modulador de receptor canabinoide CR8152A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003182039 2003-06-26

Publications (1)

Publication Number Publication Date
CR8152A true CR8152A (es) 2007-08-28

Family

ID=33549544

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8152A CR8152A (es) 2003-06-26 2005-12-15 Modulador de receptor canabinoide

Country Status (23)

Country Link
US (4) US7465815B2 (es)
EP (1) EP1637527B1 (es)
KR (1) KR101138673B1 (es)
CN (1) CN1816536B (es)
AU (1) AU2004252005B2 (es)
BR (1) BRPI0411740A (es)
CA (1) CA2531020C (es)
CO (1) CO5650243A2 (es)
CR (1) CR8152A (es)
CY (1) CY1114472T1 (es)
DK (1) DK1637527T3 (es)
ES (1) ES2420932T3 (es)
HR (1) HRP20130638T1 (es)
IL (1) IL172577A0 (es)
MX (1) MXPA05013652A (es)
NO (1) NO335769B1 (es)
NZ (1) NZ544298A (es)
PL (1) PL1637527T3 (es)
PT (1) PT1637527E (es)
SI (1) SI1637527T1 (es)
TW (1) TWI329013B (es)
WO (1) WO2005000829A1 (es)
ZA (1) ZA200510304B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2527877A1 (en) * 2003-06-18 2005-01-13 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
HRP20130638T1 (en) * 2003-06-26 2013-08-31 Takeda Pharmaceutical Company Limited Cannabinoid receptor modulator
WO2006066987A1 (en) 2004-12-22 2006-06-29 Ciba Specialty Chemicals Holding Inc. Anti-radical agents
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
US9079854B2 (en) 2007-07-13 2015-07-14 The Cleveland Clinic Foundation Hydrazone modulators of cannabinoid receptors
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
US8440832B2 (en) * 2007-07-13 2013-05-14 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
WO2009012227A1 (en) * 2007-07-13 2009-01-22 Board Of Regents, The University Of Texas System Hydrazone modulators of cannabinoid receptors
MX2010005931A (es) 2007-11-30 2010-06-15 Alltranz Inc Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
US8288390B2 (en) 2009-03-10 2012-10-16 Takeda Pharmaceutical Company Limited Benzofuran derivatives
WO2011072336A1 (en) * 2009-12-18 2011-06-23 The University Of Sydney Antiviral agents
CN103748085A (zh) 2011-06-09 2014-04-23 诺华股份有限公司 杂环磺酰胺衍生物
WO2013025984A2 (en) * 2011-08-18 2013-02-21 Temple University Cannabinoid receptor treatments
JP2015530360A (ja) 2012-07-13 2015-10-15 ザ クリーブランド クリニック ファウンデーションＴｈｅ Ｃｌｅｖｅｌａｎｄ ＣｌｉｎｉｃＦｏｕｎｄａｔｉｏｎ 神経保護ｃｂ２受容体アゴニスト
CN105878251B (zh) * 2016-04-22 2019-04-09 上海市同济医院 帕金森病动物模型的制备方法及其用途
CN107935981B (zh) * 2016-10-12 2020-10-09 中国科学院上海药物研究所 3,4-二氢-1-苯并氧杂卓类衍生物、其制备方法和用途
CN109503533B (zh) * 2019-01-04 2022-06-24 湖南大学 一种苯并呋喃酮类化合物及其高效催化合成方法
CN111072613B (zh) * 2019-11-29 2023-03-24 五邑大学 一类松萝酸类衍生物及其制备方法和在制备抗老年痴呆药物中的应用
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CN117624095B (zh) * 2023-11-28 2024-09-13 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种新型手性二氢苯并呋喃酰胺的合成方法及其应用
WO2025140655A1 (en) * 2023-12-30 2025-07-03 Fujian Haixi Pharmaceuticals Co., Ltd. Heteroaryl compounds as multi-target protein kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE68675B1 (en) * 1990-11-01 1996-07-10 Takeda Chemical Industries Ltd Aminocoumaran derivatives their production and use
WO1992012144A1 (en) * 1990-12-28 1992-07-23 Teijin Limited Condensed benzoxa ring compound, production thereof, and pharmaceutical composition containing the same
EP0539709A1 (en) * 1991-09-18 1993-05-05 FUJIREBIO Inc. 3,5-Dihydroxyheptanoic acid derivatives and lactones thereof as HMG-CoA reductase inhibitors
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5684002A (en) * 1994-09-07 1997-11-04 The Procter & Gamble Company Dihydorbenzofuran and related compounds useful as anti-inflammatory agents
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5684041A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
ATE234298T1 (de) * 1996-08-29 2003-03-15 Takeda Chemical Industries Ltd Zyklische etherverbindungen als natriumkanal- modulatoren
JP4160136B2 (ja) * 1996-08-29 2008-10-01 武田薬品工業株式会社 縮合環状エーテル類、その製造法および剤
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
US7008950B1 (en) * 1997-06-05 2006-03-07 Takeda Chemical Industries, Ltd. Benzofurans as suppressors of neurodegeneration
WO2000034262A1 (en) 1998-12-04 2000-06-15 Takeda Chemical Industries, Ltd. Benzofuran derivatives, process for the preparation of the same and uses thereof
DE69930308T2 (de) 1998-12-11 2006-11-30 Virginia Commonwealth University Selektive 5-ht 6-rezeptor-liganden
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
CA2382418A1 (en) * 1999-08-20 2001-03-01 Shigenori Ohkawa Dihydrobenzofuran derivatives, process for preparing thereof and agents
ES2317935T3 (es) * 2000-10-05 2009-05-01 Takeda Pharmaceutical Company Limited Promotores de la proliferacion y diferenciacion de celulas pluripotenciales y/o celulas precursoras neuronales.
JP2002348239A (ja) * 2000-10-05 2002-12-04 Takeda Chem Ind Ltd 幹細胞・神経前駆細胞の増殖・分化促進剤
AUPR118000A0 (en) 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
US7208495B2 (en) * 2001-07-05 2007-04-24 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
HRP20130638T1 (en) * 2003-06-26 2013-08-31 Takeda Pharmaceutical Company Limited Cannabinoid receptor modulator

Also Published As

Publication number Publication date
PL1637527T3 (pl) 2013-09-30
TWI329013B (en) 2010-08-21
DK1637527T3 (da) 2013-07-01
NO20060426L (no) 2006-02-07
US20070099990A1 (en) 2007-05-03
NZ544298A (en) 2009-04-30
TW200503686A (en) 2005-02-01
CN1816536A (zh) 2006-08-09
IL172577A0 (en) 2006-04-10
US20100240743A1 (en) 2010-09-23
AU2004252005B2 (en) 2010-02-18
BRPI0411740A (pt) 2006-05-23
CA2531020C (en) 2014-03-25
WO2005000829A1 (ja) 2005-01-06
EP1637527B1 (en) 2013-04-17
ZA200510304B (en) 2007-04-25
CN1816536B (zh) 2012-12-26
HRP20130638T1 (en) 2013-08-31
SI1637527T1 (sl) 2013-07-31
ES2420932T3 (es) 2013-08-27
CY1114472T1 (el) 2016-10-05
NO335769B1 (no) 2015-02-09
EP1637527A1 (en) 2006-03-22
EP1637527A4 (en) 2008-09-10
US20080021087A1 (en) 2008-01-24
US7465815B2 (en) 2008-12-16
CO5650243A2 (es) 2006-06-30
AU2004252005A1 (en) 2005-01-06
KR101138673B1 (ko) 2012-04-24
MXPA05013652A (es) 2006-02-24
KR20060066677A (ko) 2006-06-16
CA2531020A1 (en) 2005-01-06
PT1637527E (pt) 2013-06-28
HK1088305A1 (en) 2006-11-03
US20090023800A1 (en) 2009-01-22
US7507841B2 (en) 2009-03-24

Similar Documents

Publication Publication Date Title
CR8152A (es) Modulador de receptor canabinoide
HRP20120323T1 (en) Diarylhydantoin compounds
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
NL1028947A1 (nl) Gesubstitueerde methylaryl- of heteroarylamideverbindingen.
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CY1108649T1 (el) Υποκατεστημενα αρυλπυραζολια ως παρασιτοκτονα
EA200600620A1 (ru) Набор для ингаляции с ингаляционным порошком, содержащим тиотропий
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20082191L (no) Forbindelser
CR20110432A (es) Pirimidinas fusionadas
EA200802210A1 (ru) Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
MX2007004179A (es) Derivados de triazolpiridina como agentes antibacterianos.
CR11266A (es) Derivados de pirrolidin-2ona como moduladores del receptor de androgeno
ECSP045221A (es) Sales de valsartan
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
ECSP066392A (es)
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EA200700982A1 (ru) Производные хинолина и изохинолина, замещённые в 5-ом положении, способ их получения и их применение в качестве противовоспалительных средств
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof